SynthesisFrontiers in medicine2025
Incidence and predictors of pulmonary aspergillosis in patients with lung cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Meta-Analysis on the Incidence and Associated Factors of Pulmonary Fungal Infections in Lung Cancer Patients: Evidence Predominantly From Chinese Studies in the Chinese and English Literature.Thoracic cancer · 2026Pooled it
- Salvage sleeve-pneumonectomy for a malignant bronchomediastinal fistula and the feasibility of a modified tritubeJournal of cardiothoracic surgery · 2026Article
- Tuberculosis Preceding Lung Cancer: A Contemporary Meta-Analysis Revealing a Critical Gap in Post-2020 Evidence.Cancers · 2026Review
- Aspergillosis: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Journal of fungi (Basel, Switzerland) · 2026Review
- Epidemiology, Risk Factors, and Routine Blood Biomarkers of Aspergillosis in Cancer Patients in Jiangxi, China.Infection and drug resistance · 2026Article
- Independent Risk Factors and Nomogram-Based Prediction of Pulmonary Fungal Infection in Lung Cancer Inpatients: A Single-Center Retrospective Study.Cancer management and research · 2026Article
- Development and validation of an interpretable machine learning model for the early diagnosis of invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
- Pathogen spectrum and management strategies for opportunistic infections in lung cancer in the immunotherapy era: recent advances from fungi to mycobacteria.American journal of cancer research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary aspergillosis is a rare but serious complication following lung cancer surgery, increasing the risk of mortality. The incidence of pulmonary aspergillosis and its risk factors among lung cancer patients is unknown. This study systematically investigates the incidence and associated risk factors of pulmonary aspergillosis in lung cancer patients. Methods: The databases PubMed, Web of Science, Scopus, Embase, CINAHL, and the Cochrane Library were comprehensively searched from their inception to March 2025. The overall incidence of pulmonary aspergillosis among lung cancer patients was analyzed using a random-effects model with logit transformation. Risk factors for pulmonary aspergillosis in lung cancer patients were presented as odds ratios (ORs) with 95% confidence intervals (CIs), calculated using a random-effects model. Results: Nine retrospective studies involving 20,138 patients with lung cancer were selected for the final analysis. The overall incidence of pulmonary aspergillosis in lung cancer patients was 2.4% (95% confidence interval [CI]: 1.5-3.2%). Subgroup analyses revealed higher incidences of pulmonary aspergillosis than corresponding subgroups in the following categories: Asia (2.8%; 95% CI: 2.0-3.7%), diagnosis by serological test (11.7%; 95% CI: 8.0-15.4%), patients with both non-small cell lung cancer and small cell lung cancers (3.6%; 95% CI: 2.0-5.2%), patients treated with chemoradiotherapy (5.7%; 95% CI: 1.6-9.7%), and pooled studies with moderate quality (2.9%; 95% CI: 1.7-3.2%). Moreover, the risk factors for pulmonary aspergillosis in lung cancer patients included male sex (OR: 1.96; Conclusion: Our study highlights pulmonary aspergillosis as a significant complication in lung cancer patients, with an overall incidence of 2.4%. The identified risk factors provide crucial insights for targeted screening and intervention in this patient population. Future research should focus on validating these findings in prospective studies and exploring the underlying biological mechanisms to develop more effective preventive and treatment strategies. Systematic review registration: This study was registered in the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY) platform (number: INPLASY2024100066).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.